D
espite improvements in prevention, burn injury continues to represent a major threat to the health and welfare of people worldwide in all age groups. Each year in the United States alone, approximately 100,000 people are hospitalized for burn injury. Of these patients, 20% require treatment in a burn intensive care unit (ICU), and approximately 5% die of burn-related injuries (1) (2) (3) . Despite early surgical intervention and aggressive antibiotic therapy, infectious complications are a major cause of death in severe burn injury, accounting for approximately 75% of all deaths occurring after initial resuscitation (4) . One source of these infections is thought to be translocation of Gram-negative bacteria from the gut (5-7). Glutamine (GLN) deficiency may contribute to both of these processes because GLN is the preferential nutrient source for both lymphocytes and enterocytes (8, 9) Animal models demonstrate that GLN supplementation can decrease gut-derived bacterial translocation and improve outcome from burn injury (10, 11) . Additionally, we have shown that GLN supplementation induces heat shock protein (both in vitro and in vivo) and improves survival from endotoxin-induced septic shock (12, 13) . Induction of heat shock protein by sodium arsenite recently was shown to decrease bacterial translocation and improve outcome in a rat model of gut-origin burn sepsis (14). In humans, GLN has been shown to prevent infectious morbidity and mortality in a group of bone marrow transplant patients (15) . Furthermore, a recent study of patients with multiple trauma showed that GLN administration decreased the occurrence of sepsis, pneumonia, and bacteremia (16) . Specifically, this study demonstrated that patients supplemented with GLN had no episodes of Gram-negative bacteremia.
Burn injury is known to markedly deplete GLN (17) , which may increase the incidence of gut atrophy and immune dysfunction and potentially increase the incidence of Gram-negative bacteremia. In this pilot trial we investigated the effect of intravenous GLN supplementation on the occurrence of bacteremia and other infectious morbidity in patients with severe burns. We also measured overall nutritional status and inflammation.
METHODS
Patients. Thirty-one consecutive patients with severe burns, admitted to the University of Chicago Burn Intensive Care Unit within 72 hrs of their injury, were assessed for entry into a double-blind, randomized, controlled trial to test the clinical efficacy of GLN vs. an isonitrogenous control. Criteria for entry into the study were age Ͼ2 yrs, admission within 72 hrs of burn injury, and total burn surface area Ͼ25%. Exclusion criteria included severe hepatic or renal disease, pregnancy, death within 72 hrs of admission, or inability to obtain informed consent from patient or suitable proxy. After admission to the burn unit, the participating pharmacist used a computergenerated randomization process to control randomization. Characteristics and burn size of the patients are presented in Table 1 . All the patients were assessed by one of two physicians (MDK or LJG). Patients were cared for by an identical staff of surgeons and intensivists and thereby benefited from standardized care procedures, including early excision and grafting. The Institutional Review Board of the University of Chicago approved this study, and informed consent was given either by patients or by a suitable proxy.
Feeding Protocol. Patients received nutritional support as directed by a single dietitian who saw all patients. All patients were started on enteral feeding within 48 hrs of admission and were advanced to reach a goal caloric intake based on resting energy expenditure in intubated patients (this intake was monitored continuously for the period of intubation). In nonintubated patients, a caloric goal of 30 kcal/kg body weight/day was set, with 20% of calories given as protein. Supplemental GLN or control solutions were not taken into account in calculating caloric or protein intake goals. All patients were started on Pro-Balance (Nestle, Deerfield, IL), a commercially available enteral diet that contained no added Lglutamine or other immunonutrients (such as omega-3 fatty acids or arginine). Patients who could not tolerate enteral feedings during hospitalization were supplemented with parenteral nutrition support until enteral feeds could be tolerated.
Treatment. Patients were randomized to receive either intravenous GLN or an isonitrogenous control amino acid solution. All patients had experimental or control therapy initiated within 48 hrs of admission. The experimental or control therapy was continued for the duration of the burn ICU stay. Per protocol, subjects were discontinued from study if their serum ammonia concentration was Ͼ200 g/dl. Patients were required to receive the GLN or control solution for Ͼ7 days for their results to be eligible for analysis. Intravenous solutions were formulated by IVONYX clinical pharmacy (Memphis, TN). The GLN solution was mixed to provide 0.57 g ·kg Ϫ1 ·day Ϫ1 L-glutamine. This dose was given as a continuous infusion over 24 hrs. The control solution consisted of an isonitrogenous amino acid solution (FreAmine, BraunMcgaw, Atlanta, GA) mixed to provide 0.57 g· kg Ϫ1 ·day Ϫ1 mixed amino acids. This amino acid solution was a mixture of essential and nonessential amino acids (not containing GLN). Unlabeled bags containing the appropriate solution were delivered to each patient daily so that investigators, patients, and burn center staff were blinded to randomization. The two solutions were identical in appearance.
Clinical Outcomes. Patients were monitored for the presence of positive blood cultures and antibiotic use for 30 days (1 month) after admission to the burn unit. The decision to initiate blood cultures or antibiotic therapy was directed by the clinical judgment of the attending intensivist, who was blinded as to the patients' randomization within the study. Antibiotic use was calculated by a daily tabulation of all intravenous or oral antimicrobial agents begun after day 0 (e.g., three antibiotics given in 1 day would count as 3 antibiotic days) divided by 30 days or total time in burn unit if Ͻ30 days. Patients also were followed for their entire hospital stay for mortality, date of first surgery, total number of surgeries, length of stay in the burn ICU, and total hospital length of stay.
Laboratory Tests. Blood samples were collected on days 1, 7, and 14 for analysis of transferrin, prealbumin, and C-reactive protein concentrations. Because possible complications of GLN administration are elevations of ammonia and liver function abnormalities, blood samples were taken at study entry and then once weekly during burn unit stay to measure ammonia and liver enzymes for the duration of the study period. The University of Chicago Clinical Laboratories performed all aforementioned tests.
Statistical Analysis. This study was performed as a pilot study, and the number of patients was determined by the number of eligible patients admitted over an 18-month period. Differences in number of bacteremia and other qualitative parameters were compared by using the chi-square test. Laboratory data means between groups were analyzed by unpaired Student's t-test. Length of stay data and peak ammonia, bilirubin, and serum glutamic-oxaloacetic transaminase were analyzed by the Mann-Whitney U test. The level of significance was set at p Ͻ .05.
RESULTS
Between February 1998 and August 1999, 31 patients with severe burns were admitted to the burn center at the University of Chicago. The flow of patients is demonstrated in Figure 1 . Three patients in the GLN group were excluded (two patients Ͻ2 yrs of age, one patient who died in the first 3 days postinjury of early septic shock), as were two patients in the control group (one patient for whom we were unable to obtain consent in first 48 hrs postinjury and one patient who died of septic shock in the first 3 days postinjury). These patients were excluded from analysis. All remaining patients received the GLN or control supplementation Ͼ7 days. Two patients in the GLN group and one patient in the control group were ultimately discontinued from the study because of elevated ammonia concentrations. These patients were discontinued from the study Ͼ30 days after injury, so their data are included in the analysis. Two of these patients (one patient in the GLN group and one in the control group) died of multiorgan failure within 3 days of being discontinued from the study because of the elevated ammonia concentrations.
The characteristics of the remaining 26 patients are presented in Table 1 . There were no differences between groups for age, gender ratio, total body surface area burned, percentage of third-degree burns, occurrence of inhalation injury, or need for mechanical ventilation at admission. Data on nutritional intake of the two patient groups are shown in Table 2 . Average daily nitrogen intake does not include that provided by GLN or control solutions. There was no difference in average caloric intake, nitrogen intake, admission resting energy expenditure, or patients receiving parenteral nutrition over the study period. Furthermore, in patients receiving total parenteral nutrition, there was no statistical difference in the mean number of days patients received parenteral nutrition support. However, patients receiving GLN showed a modest trend toward requiring fewer days of parenteral nutrition support (p Ͻ .09).
Incidence of bacteremia as measured by positive blood cultures is listed in Table 3 . There was no difference in the average number of blood cultures drawn per patient (GLN 17.6 Ϯ 3.6 vs. control 20.7 Ϯ 3.5, p ϭ .53). There was a significant decrease in the incidence of Gram-negative bacteremia (p Ͻ .04) in the GLN-treated patients over the first 30 days after burn injury. The incidence of patients with Gram-positive bacteremia or fungemia did not differ between groups. The total number of patients with positive blood cultures did not differ between groups. A noticeable but not statistically significant decrease in the average number of positive blood cultures per patient was observed (p Ͻ .10), as well as a nonsignificant decrease in the average antibiotic usage per day (p Ͻ .15). Outcome data are shown in Table 4 . There was one death in the GLN group vs. four in the control group (p Ͻ .19). There was no difference in the median stay in the ICU or total days in the hospital. Data from patients who died during the study period or who were discontinued because of elevated ammonia concentrations are not included in the analysis of length of stay. Number of days to first surgery and total number of surgeries during burn unit stay were not significantly different between the two groups, although patients receiving GLN had a median ICU stay that was 6.5 days shorter than patients in the control group (nonsignificant by MannWhitney U test).
There was no difference in admission measures of nutritional status (trans- ferrin and prealbumin; Figs. 2 and 3) ; however, GLN-treated patients demonstrated a significant improvement in both prealbumin (p Ͻ .04) and transferrin (p Ͻ .01) on day 14 postinjury (Figs. 2 and  3 ). GLN significantly decreased C-reactive protein (a measure of overall inflammation) at 14 days postinjury (p Ͻ .01; Fig. 4 ). Other laboratory values revealed no change in median peak ammonia, bilirubin, or serum glutamic-oxaloacetic transaminase between groups (nonsignificant by Mann-Whitney U test).
DISCUSSION
We found that supplementation of parenteral GLN (in addition to standard nutrition support) reduced the incidence of Gram-negative bacteremia, decreased overall inflammation, and improved nutritional status in severely burned patients. GLN supplementation also led to nonsignificant decreases in the average number of positive blood cultures and antibiotic use per patient. The groups had similar demographics, burn size, incidence of inhalation injury, need for mechanical ventilation, and number of operations. Patients were typically young male subjects who were in good health before their injury. As indicated by the average burn size (~50%) these were severely burned patients, half of whom also had a significant inhalation injury. All patients presented with full-thickness burn areas.
A number of studies (15, 16, 18, 19) have shown beneficial effects of GLN given enterally or as a supplement to parenteral nutrition in seriously ill patients. This study is unique for two reasons: a) it used intravenous GLN as a pharmacologic intervention (in addition to standard enteral nutrition support) rather than as a supplement to total parenteral nutrition; and b) it examined the effect of GLN in severely burned patients. Enteral nutrition has become the preferred method of feeding in severely burned patients because there are fewer infections compared with parenteral feeding (5). Furthermore, enteral feeding is thought to preserve gut barrier function and prevent gut atrophy more effectively then parenteral nutrition (5). However, studies in critically ill patients that use oral GLN supplements have not consistently shown increases in plasma GLN concentration (20) . As a result, we administered the GLN supplement as a continuous intravenous infusion. GLN supplementation was well tolerated with little evidence of significant elevations of ammonia or liver function tests in either group. Three patients (two in the GLN group and one in the control group) had a significant increase in ammonia during the study period and were discontinued from the protocol. All three of these patients had acute renal failure (requiring dialysis) and significant liver dysfunction at the time of the elevated ammonia, and two died within 3 days of being discontinued from the study (one in each group). It is likely that any significant protein load, whether from GLN or other amino acids, would have significantly increased ammonia in these patients given their multiorgan failure. These data seem to indicate that ammonia concentrations should be followed closely in patients on supplemental GLN with fulminate renal or liver failure. However, mild to moder- ate liver and renal dysfunction did not seem to elevate ammonia concentrations in GLN-supplemented or control patients.
The frequency of Gram-negative bacteremia was 43% in the control group vs. 8% (one patient) in the GLN group. This difference was statistically significant, although this result occurred in a small number of patients and should be confirmed in a larger trial. However, these data are consistent with the results of a previous trial of GLN in multiply traumatized patients (16) . That study demonstrated a statistically significant reduction in the incidence of bacteremia, septic episodes, and pneumonia in GLNtreated patients vs. an isonitrogenous control. The previous study (16) also showed that GLN supplementation had a particularly dramatic effect on the incidence of Gram-negative bacteremia. No patients in the GLN-treated group had a Gram-negative bacteremia, whereas 54% of the bacteremias and 63% of the causes of sepsis in the control group were attributable to Gram-negative organisms. The results of our study and the study of multiple trauma patients support the hypothesis that GLN may enhance gut barrier function and prevent bacterial translocation from the gut. Neither trial was designed to specifically examine this, and so no clear conclusions can be drawn. However, in support of this hypothesis, trials of GLN supplementation in burned animals indicate that GLN can prevent the translocation of radiolabeled bacteria across the gut barrier. Furthermore, as a primary respiratory fuel for the enterocytes and colonocytes, GLN supplementation has been shown to prevent increases in gut atrophy and permeability related to total parenteral nutrition (21) . We also observed a marked decrease in the average number of positive blood cultures per patient and in overall daily antibiotic use; however, these differences did not achieve the desired p Ͻ .05. It is possible that this failure to achieve statistical significance was attributable to a relatively small sample size, and a larger trial is warranted to confirm these results. No difference was seen in the incidence of Gram-positive bacteremia. These are primarily skin-derived organisms, and these results suggest that GLN does not prevent translocation of bacteria from burn eschar.
The study also demonstrated that GLN supplementation decreased overall inflammation as measured by C-reactive protein. This finding is consistent with the results of the aforementioned study (16) , in which trauma patients receiving GLN showed decreases in serum concentrations of soluble tumor necrosis factor receptors. These results suggest that GLN decreases the overall systemic inflammatory response, which may be related to the relative decrease in bacteremia in GLN-treated patients. Another explanation is that GLN may directly affect the release of proinflammatory cytokines, as we previously showed in an animal model of septic shock (13) .
Our results indicate that GLN supplementation can improve measures of nutritional status. Specifically, prealbumin and transferrin were significantly increased at 14 days after admission. This occurred despite similar caloric and nitrogen intakes in the two groups. This may be attributable to improved gut function, because GLN is the most important respiratory fuel for the small bowel. Alternatively, this may be attributable to decreased systemic inflammatory response in GLN-treated patients, given that increases in tumor necrosis factor-␣ and other proinflammatory cytokines induce a catabolic state.
Despite the attenuation of infectious morbidity and systemic inflammation and the improvement in nutritional parameters, a significant decrease in overall mortality was not observed. However, there was only one death in the GLN treatment group, and this occurred in a patient who was 70 yrs of age. There were four deaths in the control group. A larger trial would be necessary to critically examine the effect of GLN on mortality. Furthermore, GLN supplementation did not significantly affect ICU and total hospital length of stay, as has been seen in some other trials of GLN supplementation of seriously ill patients (15) . However, patients treated with GLN demonstrated a trend toward a decreased ICU length of stay. Again, it is likely that a larger trial is necessary to examine this question effectively. 
CONCLUSION
We have shown that GLN treatment given as a supplement to standard enteral nutrition decreases the incidence of Gram-negative bacteremia, attenuates measures of overall inflammation, and improves nutritional status in severely burned patients. The precise mechanisms for the beneficial effects of GLN are not clear. Furthermore, this study involved a small number of patients and therefore must be viewed as preliminary. However, the results of this study support the use of GLN in severely burned patients, and larger clinical trials that use GLN as a pharmacologic intervention in this patient population clearly are warranted.
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